Phase III ORIENT-32 trial of Tyvyt (sintilimab injection) in combination with Byvasda (bevacizumab biosimilar) as first-line treatment of patients with advanced hepatocellular carcinoma meets primary endpoints

Based on interim analysis, the combination regimen demonstrated a statistically significant improvement in progression-free survival and overall survival compared with sorafenib, with no new safety signals identified. Data will be presented at upcoming medical conference.

Biospace Inc.